Skip to content
PICO PortalSearch builder

Strategy check

Check of an existing strategy

DoneStarted Oct 28, 2026, 20:17 UTCFinished Oct 28, 2026, 20:17 UTC

Stages

  1. Reading the strategy(done)
  2. Checking MeSH(done)
  3. Counting in PubMed(done)
  4. Run Search(done)
  5. Saving(done)
Run log (9)
  1. Reading the strategy: Reading the numbered search lines
  2. Checking MeSH: Checking 2 vocabulary terms against NLM MeSH
  3. Counting in PubMed: Running 3 lines on PubMed
  4. Line 1: 204,451 records
  5. Line 2: 10,378 records
  6. Line 3: 4,461 records
  7. Run Search: Fetching the first 20 records of line 3
  8. Saving: Saving the run
  9. Finished.

Final count (line 3)

4,461

Open in PubMed (opens in a new tab)
Query as run (112 characters)("Diabetes Mellitus, Type 2"[Mesh]) AND ("Glucagon-Like Peptide-1 Receptor Agonists"[Mesh] OR semaglutide[tiab])

Search lines

Vocabulary terms are marked ✓︎ valid, ↪︎ mapped to the preferred heading, ✗︎ not found, ⚠︎ not checked.
Numbered search lines with their PubMed counts and the counts reported in the document
No.SearchResults(reported)
1"Diabetes Mellitus, Type 2"[Mesh] (MeSH heading valid: D003924)204,451no reported count
2"Glucagon-Like Peptide-1 Receptor Agonists"[Mesh] (MeSH heading valid: D000097789) OR semaglutide[tiab]10,378no reported count
3Final#1 AND #24,461no reported count

Issues

No issues found.

First records

The first 20 of the final line's records, as PubMed sorts them.
  1. Comparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database. (PubMed, opens in a new tab)

    Yildirim BO, Sarkim IF, Yalman G et al. · BMC cardiovascular disorders · 2026 · PMID 42947001

  2. Semaglutide and Panic Attacks: Active-Comparator Disproportionality Analysis, Temporal Assessment of Notoriety Bias and Evidence Triangulation in Post-Marketing Pharmacovigilance. (PubMed, opens in a new tab)

    Melamed B, Parsi-Zahabi M, Omrani MA et al. · Pharmacoepidemiology and drug safety · 2026 · PMID 42946127

  3. GLP-1 RA Prescribing in Patients With Type 2 Diabetes and Cancer. (PubMed, opens in a new tab)

    Hu X, Jiang C, Han X et al. · JAMA network open · 2026 · PMID 42944687

  4. Prescribing SGLTis and GLP-1 RAs for Patients With Type 2 Diabetes, Guideline Updates, and Longitudinal Knowledge Assessment Scores. (PubMed, opens in a new tab)

    Gray BM, Vandergrift J, Landon BE et al. · JAMA network open · 2026 · PMID 42944684

  5. Impact of GLP-1 Receptor Agonists on Cognitive Performance in Adults at Risk of Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. (PubMed, opens in a new tab)

    Abbatecola AM, Migliara G, D'Agostino F et al. · Nutrients · 2026 · PMID 42942883

  6. GLP-1 Receptor Agonist Therapy in Patients with Cancer: A Review of Clinical Outcomes. (PubMed, opens in a new tab)

    Andronescu AC, Ciumărnean L, Orășan OH et al. · International journal of molecular sciences · 2026 · PMID 42942021

  7. Association of Glucagon-like Peptide-1 Receptor Agonists Versus Dipeptidyl Peptidase-4 Inhibitors with Tuberculosis and Mortality in Adults with Diabetes. (PubMed, opens in a new tab)

    Hsu CH, Chang R, Chen CF et al. · International journal of molecular sciences · 2026 · PMID 42941904

  8. Efficacy and safety of GLP-1 receptor agonists in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH): A systematic review and meta-analysis. (PubMed, opens in a new tab)

    Alfawaz M, Bajamaan D, Alghamdi L et al. · Medicine · 2026 · PMID 42937793

  9. GLP-1-based therapies in cardiovascular disease: outcomes, mechanisms, and emerging clinical applications. (PubMed, opens in a new tab)

    Jang R, Jang M, Ruan X et al. · European journal of clinical pharmacology · 2026 · PMID 42918905

  10. Oral Small-Molecule GLP-1 Receptor Agonists: Lessons from Clinical Candidates and a Blueprint for Next-Generation Design. (PubMed, opens in a new tab)

    Hu J, Zhang Y, Wang M et al. · Journal of medicinal chemistry · 2026 · PMID 42916694

  11. Association of GLP-1 Receptor Agonist Use with Thyroid Outcomes in Adults with Type 2 Diabetes. (PubMed, opens in a new tab)

    Hsiao CC, Tsai MH, Jhu JY et al. · International journal of medical sciences · 2026 · PMID 42910111

  12. Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies. (PubMed, opens in a new tab)

    Kounatidis DC, Vallianou NG, Kouveletsou M et al. · Current obesity reports · 2026 · PMID 42905300

  13. Real-world Challenges and Predictors of Success in Glucagon-like Peptide-1 Receptor Agonist Therapy. (PubMed, opens in a new tab)

    Patankar NM, Sanghvi SJ · The Journal of the Association of Physicians of India · 2026 · PMID 42902671

  14. Effectiveness of Weekly Semaglutide Treatment (0.5 or 1 mg) in Chilean Patients with Type 2 Diabetes Mellitus. (PubMed, opens in a new tab)

    Estica M, Godoy G, Vargas C et al. · Revista medica de Chile · 2026 · PMID 42899606

  15. Glucagon-like peptide-1 receptor agonists and aesthetic surgery: perioperative safety, timing, durability and body composition. (PubMed, opens in a new tab)

    Chaturvedi R, Singh K, Chakole RR et al. · Frontiers in endocrinology · 2026 · PMID 42898660

  16. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis. (PubMed, opens in a new tab)

    Rasool ZK, Shah R, Batool AEZ et al. · Frontiers in endocrinology · 2026 · PMID 42890523

  17. Pharmacy students' knowledge and attitudes regarding GLP-1 receptor agonist adverse effects in obesity management: a cross-sectional study. (PubMed, opens in a new tab)

    Khojah AA, Gazzaz MJ, Aldurdunji MM et al. · The Libyan journal of medicine · 2026 · PMID 42886550

  18. Glucagon-Like Peptide-1 Receptor Agonists and Incident Cardiovascular Events and Death in Treated Serious Mental Illness, Type 2 Diabetes, and Obesity. (PubMed, opens in a new tab)

    Governor SB, Dávila-García DM, Rivera-Segarra E et al. · Journal of the American Heart Association · 2026 · PMID 42885796

  19. GLP-1 receptor agonist initiation and risk of psychiatric hospitalisation and emergency department presentation in adults with schizophrenia and type 2 diabetes in the USA: an observational cohort study using electronic health records data. (PubMed, opens in a new tab)

    Davoodian N, Williams LJ, Berk M et al. · The lancet. Psychiatry · 2026 · PMID 42874603

  20. Values, preferences, and treatment burden for initiation of GLP-1 receptor agonists, SGLT-2 inhibitors, tirzepatide, and finerenone in adults with type 2 diabetes: systematic review. (PubMed, opens in a new tab)

    González-Cruz DC, Garcia-Campa M, Moreno-Peña PJ et al. · BMJ medicine · 2026 · PMID 42866418

Export

Strategy (.txt)PMIDs (.txt)MEDLINE (.txt)Provenance (.json)

The strategy file has the numbered lines with counts, the search date and the AI-use statement. MEDLINE holds the first 2,000 records. PMIDs and MEDLINE are fetched from PubMed when you download, so they reflect PubMed today.

Checking PubMed for the current list of PMIDs…